Stock 603590 BEIJING KONRUNS PHARMACEUTICAL CO.,LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Beijing Konruns Pharmaceutical Co.,Ltd.

Equities

603590

CNE1000036K3

End-of-day quote Shanghai S.E.
Other stock markets
 06:00:00 2024-04-28 pm EDT 		5-day change 1st Jan Change
29.84 CNY +1.22% Intraday chart for Beijing Konruns Pharmaceutical Co.,Ltd. +2.54% -21.64%
Apr. 25 Beijing Konruns Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Apr. 08 Beijing Konruns Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Strengths

  • Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • The group's high margin levels account for strong profits.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • Analyst opinion has improved significantly over the past four months.
  • Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.

Weaknesses

  • The firm trades with high earnings multiples: 25.29 times its 2024 earnings per share.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
  • Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
BEIJING KONRUNS PHARMACEUTICAL CO.,LTD. Stock Beijing Konruns Pharmaceutical Co.,Ltd.
-21.64% 645M -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+26.47% 664B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+26.74% 567B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.33% 354B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.35% 330B
B-
ABBVIE INC. Stock AbbVie Inc.
+4.23% 286B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.43% 234B
B+
NOVARTIS AG Stock Novartis AG
+4.71% 199B
B-
ROCHE HOLDING AG Stock Roche Holding AG
-9.53% 196B
A+
AMGEN INC. Stock Amgen Inc.
-4.04% 148B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
-
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
-
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 603590 Stock
  4. Ratings Beijing Konruns Pharmaceutical Co.,Ltd.